Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China

• Main Authors: Hao Wang (Author), Ye Wang (Author), Li Li (Author), Han Zhou (Author), Shang Lili (Author), Liao Li (Author), Shen Yike (Author), Ma Aixia (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundIn the Checkmate9ER trial, first-line treatment with nivolumab combined with cabozantinib (NI + CA) has shown efficacy for advanced renal cell carcinoma. This study aims to evaluate the impact of the health and economic outcomes of NI + CA in China.MethodsClinical efficacy data were derive...